首页> 美国卫生研究院文献>PLoS Clinical Trials >Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging
【2h】

Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging

机译:他克莫司从基于水凝胶的药物递送系统中的局部释放在体内受到炎症酶的控制,可以使用体内成像技术进行无创监测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLocal drug delivery systems that adjust the release of immunosuppressive drug in response to the nature and intensity of inflammation represent a promising approach to reduce systemic immunosuppression and its side effects in allotransplantation. Here we aimed to demonstrate that release of tacrolimus from triglycerol monostearate hydrogel is inflammation-dependent in vivo. We further report that by loading the hydrogel with a near-infrared dye, it is possible to monitor drug release non-invasively in an in vivo model of vascularized composite allotransplantation.
机译:背景技术响应炎症的性质和强度而调节免疫抑制药物释放的局部药物递送系统代表了减少全身免疫抑制及其在同种异体移植中的副作用的有前途的方法。在这里我们旨在证明他克莫司从单硬脂酸甘油三酯水凝胶中释放是体内炎症依赖性的。我们进一步报道,通过用近红外染料加载水凝胶,可以在血管化复合同种异体移植的体内模型中无创地监测药物释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号